NCT06911008View on ClinicalTrials.gov

MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 9, 2025

Primary Completion Date

April 9, 2027

Study Completion Date

April 9, 2027

Conditions
Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
Interventions
PROCEDURE

Biospecimen Collection

Undergo tissue and blood sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

SCD1 Inhibitor MTI-301

Given PO

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER